PR Newswire·Oct 30, 2025, 8:30 AM ET

Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain

Cryoport Systems became the first global supply chain solutions company to achieve ISO 21973:2020 certification for transporting human cells for therapeutic use.
The certification underscores Cryoport's commitment to safety, traceability, & integrity standards within the cell & gene therapy industry.
Cryoport Systems participated in the Standards Coordinating Body working group that developed the ISO 21973 requirements starting in 2020.
The standard provides comprehensive guidelines for environmental control, equipment, processes, logistics, & information to minimize risks like temperature excursions, contamination, & chain of custody breaches.
Jerrell Shelton, Chairman & CEO, stated the achievement solidifies Cryoport's position as a pioneer & follows their 2025 CPHI Award for Supply Chain Excellence.
Cryoport applies ISO 21973 standards across the life sciences spectrum, including reproductive medicine & animal health markets, alongside its proprietary Chain of Compliance ®.
Cryoport, Inc. (NASDAQ: CYRX) is headquartered in Nashville, Tennessee, with global operations across the Americas, EMEA, & APAC.
The company offers end-to-end solutions including the Cryoportal ® Logistics Management Platform, temperature-controlled packaging, biostorage, & cryogenic systems.
The press release includes standard forward-looking statements cautioning that actual results may differ due to economic, geopolitical, & technical factors.